GLP-1s Are Driving Your Renewal. Here Are the Levers Employers Use to Contain the Cost.

If your renewal came back higher than you expected this year, there is a good chance one drug category explains a large share of it. Employers are projecting health care cost increases of around 10 percent for 2026, according to the International Foundation of Employee Benefit Plans, and GLP-1 medications sit at the center of that number. The Employee Benefit Research Institute has modeled that broad GLP-1 coverage can add anywhere from 6 percent to nearly 14 percent to plan costs in a single year, even when cost-sharing is already in place.

The instinct, once those numbers land, is to treat the decision as binary: cover these drugs or do not. But most of the real cost management happens in the space between those two options. Employers who keep coverage and still control the spend are not the ones who said yes without thinking. They are the ones who put structure around how, for whom, and for how long the plan pays. This article walks through the levers that actually move the number.

Start With Where the Money Goes

A single member on a GLP-1 for weight loss costs a plan roughly $600 to $750 per month after rebates and negotiated rates, against list prices that ran between $1,000 and $1,350 per month in 2026. That is not a one-time claim. These drugs require continuous use to hold their effect, so each approved member becomes a recurring monthly cost that persists across plan years.

That persistence is the reason utilization management matters so much here. With most drug categories, tightening the rules trims a modest amount off a manageable line item. With GLP-1s, every member you do or do not approve, and every member who does or does not stay on therapy, compounds across renewals. Small differences in plan design produce large differences in cost over a three-year window.

Eligibility Criteria and Prior Authorization

The first and most common lever is defining who actually qualifies. Rather than covering anyone with a prescription, most employers route GLP-1 requests through prior authorization tied to clinical criteria. The typical standard requires a documented body mass index of 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension or sleep apnea, along with confirmation from the prescriber.

Prior authorization does two things at once. It keeps coverage anchored to clinical need rather than general demand, and it creates a documented, consistent standard that is easier to defend than case-by-case judgment calls. The administrative work is real, and your pharmacy benefits manager handles most of it, but the design choices behind the criteria are yours to set.

Step Therapy

A second lever is requiring lower-cost interventions before the plan pays for a GLP-1. Step therapy asks members to try and document other approaches first, which can include a structured weight management program or, in some plan designs, a lower-cost medication. Members who do not respond can then move to a GLP-1.

Step therapy is not popular with everyone, and it adds friction that some employees experience as a barrier. Used carefully, though, it filters spend toward the members most likely to need and benefit from the drug, rather than treating it as a first resort. The key is making the required steps genuinely reasonable, not so onerous that they read as a way to deny coverage by attrition.

Reauthorization Tied to Response

One of the more effective and underused levers is continuation criteria. Many plans now require proof of meaningful weight loss, often in the range of 5 percent of body weight, at a 6 to 12 month checkpoint in order to keep coverage active. Members who are responding stay on therapy. Members who are not are transitioned off.

This matters because it directly addresses the recurring-cost problem. Without continuation criteria, a plan keeps paying $600 to $750 a month indefinitely regardless of whether the drug is working for that member. With them, the plan keeps paying only where there is a demonstrated clinical result. It is one of the cleanest ways to align cost with value, and it is defensible precisely because it ties coverage to outcomes rather than to who asked first.

Required Lifestyle and Clinical Programs

Roughly 38 percent of employers that cover GLP-1s pair them with a required lifestyle or behavior-change program, and close to half apply some restriction beyond basic prior authorization. The logic is twofold. Pairing the medication with coaching, nutrition support, or a clinical wellness program tends to improve outcomes and adherence, which makes the spend more productive. It also sets up healthier maintenance for the day a member eventually comes off the drug, which reduces the odds of paying twice for the same problem.

For smaller employers, these programs are often delivered through a specialized vendor or a carve-out arrangement rather than built in house. The trade-off is an added per-member program cost in exchange for better results and tighter management of the medication spend itself.

PBM Positioning, Rebates, and Stop-Loss

Some of the most consequential levers are the ones employees never see. How a GLP-1 is positioned on your formulary, what rebates your pharmacy benefits manager passes through, and how your stop-loss contract treats these drugs all shape the net cost more than any single coverage rule.

This is an area worth pushing on directly with your broker and PBM. Rebate economics on this category have shifted, and in some cases worsened to the point that employers who wanted to keep partial coverage concluded the math no longer worked. On the stop-loss side, a number of carriers have started adding GLP-1-specific provisions or adjusting attachment points, which can change your exposure at renewal whether or not you change your own plan design. If you are self-insured, understanding how your stop-loss treats this category is not optional.

The Pricing Picture Is Starting to Move

The cost equation is not static. A new oral GLP-1, orforglipron from Eli Lilly, reached the market in 2026 with cash prices starting far below the injectable incumbents, in some channels around $149 per month for eligible cash-pay patients. Additional competition and lower-cost options entering the category over the next year or two could meaningfully reduce per-member cost.

This does not solve your 2026 renewal, but it should shape your strategy. Plan designs and contracts written today should leave room to take advantage of lower-cost alternatives as they become available, rather than locking into terms built around today's prices.

The Bottom Line

GLP-1 coverage is expensive, but the cost is far more controllable than a yes-or-no framing suggests. Eligibility criteria, step therapy, response-based reauthorization, required lifestyle programs, and the contract-level details of PBM and stop-loss arrangements each move the number, and together they let an employer keep a benefit employees value without absorbing the full premium hit.

One caution worth stating plainly: how you design these rules has legal dimensions, including obesity's evolving status under disability law, so coverage and eligibility decisions should be reviewed with knowledgeable benefits counsel before you implement them. The goal is not to make coverage hard to get. It is to make sure the plan pays for clinical value, documents its standards consistently, and stays sustainable across renewals.

---

Benefits Collective is an independent information resource for employers navigating benefits decisions. If GLP-1 costs are driving your renewal, schedule a consultation and we will connect you with a vetted partner for an independent analysis of your current plan.